Recent experience includes:
Bicycle Therapeutics - Bayer
Advised Bicycle Therapeutics plc on a strategic collaboration agreement with Bayer to discover and develop Bicycle radioconjugates for multiple oncology targets. Under the terms of the agreement, Bayer and Bicycle will collaborate on the development of bicyclic peptides for multiple oncology targets. Bicycle will use its proprietary phage platform to discover and develop bicyclic peptides, and Bayer will be responsible for, and fund, all further preclinical and clinical development, manufacturing, and commercialisation activities. Bicycle will receive a US$45 million upfront payment. It is also eligible to receive development and commercial-based milestone fees, totalling up to US$1.7 billion, as well as tiered royalties on Bicycle-based medicines commercialised by Bayer. The closing of the transaction was subject to clearance under the U.K. National Security and Investment Act (NSIA) 2021.
Bicycle Therapeutics – Novartis
Advised Bicycle Therapeutics on a strategic collaboration agreement with Novartis to discover and develop multiple targeted radioligand therapies in oncology. The two companies will develop, manufacture and commercialise Bicycle® radio-conjugates (BRCs) for multiple agreed upon oncology targets. Under the terms of the agreement, Bicycle will use its proprietary phage platform to discover "Bicycles" to be developed into BRCs. Novartis is responsible for further development, manufacture and commercialisation of the BRCs. Bicycle received a US$50 million upfront payment. It is also eligible to receive development and commercial-based milestone payments totalling up to US$1.7 billion, as well as tiered royalties on Bicycle-based medicines commercialised by Novartis.
Advised BenevolentAI on its recent strategic collaboration with Merck. The collaboration will use BenevolentAI’s end-to-end AI platform capabilities to deliver novel drug candidates – initially for three targets in oncology, neurology and immunology – and to identify and develop innovative compounds through Hit Identification to pre-clinical stage. Under the terms of the agreement, BenevolentAI will be eligible for payments of up to $594 million, consisting of a low double-digit million dollar upfront payment on signing and then potentially discovery, development and commercial milestones. Tiered royalties will also be payable on net sales of any commercialised products.
In addition to our longstanding role advising UCB in relation to a range of day-to-day trading agreements (including MSAs, Platform Technology collaborations and Sponsored Research Agreements), we recently advised in relation to a contract with Enable Injections, Inc., for the development and clinical supply of a wearable injection device for the delivery of rozanolixizumab, an investigational antibody for the treatment of Myasthenia Gravis, a neuromuscular disease causing weakness in skeletal muscles. We have also advised UCB in business development projects including a licensing deal in the digital health space and UCB’s compliance with Human Samples legislation and GDPR.
International pharma company
Advised in relation to a collaboration with Verily Sciences, the Google Life Sciences company, for the use of Verily’s wearable technology as part of clinical trial programme.
Management sellers of Health iQ
Advised the sellers of Health iQ, a leading provider in real world data and digital solutions for healthcare and life sciences, on its sale by way of auction process to Corrona LLC, a US leader in real world evidence. We provided the entire range of legal advice, from tax through to IP, throughout the auction process, working hand in hand with Deloitte to facilitate the sale.
Optum Venture Global Partners, LP
Advised Optum, as the lead investor, investing by way of subscription for Series A Shares, in Oxford VR Limited, resulting in Optum holding 20% of the fully diluted share capital in Oxford VR. Oxford VR is technology company which has developed immersive virtual reality software aimed at treating mental health issues such as anxiety.
Advised a global healthcare company on its mobile healthcare/related apps.